Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Optimization by PK/PD of Antibiotics for CRKP Bloodstream Infections
NCT05862402Phase 4Unknown
- Sponsor
- Phramongkutklao College of Medicine and Hospital
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
- Countries
- 1
01
Overview
Phase 4, open-label trial of ceftazidime + avibactam, meropenem, colistin, imipenem, tigecycline and 2 more in Klebsiella pneumoniae infection (2 arms), sponsored by Phramongkutklao College of Medicine and Hospital. Primary endpoint: Mortality at 14 days. Status: unknown.
02
Drugs
ceftazidime + avibactammeropenemcolistinimipenemtigecycline
03
Conditions
Klebsiella pneumoniae infection
Beyond the preview
Go deeper on NCT05862402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862402.